Roles of Fukutin, the Gene Responsible for Fukuyama-Type Congenital Muscular Dystrophy, in Neurons: Possible Involvement in Synaptic Function and Neuronal Migration by Hiroi, Atsuko et al.
Acta Histochem. Cytochem. 44 (2): 91–101, 2011
doi:10.1267/ahc.10045
© 2011 The Japan Society of Histochemistry and Cytochemistry
Advance Publication
AHC Acta Histochemica et Cytochemica 0044-5991 1347-5800 Japan Society of Histochemistry and Cytochemistry Tokyo, Japan AHC10045 10.1267/ahc.10045 Regular Article
Roles of Fukutin, the Gene Responsible for Fukuyama-Type Congenital Muscular 
Dystrophy, in Neurons: Possible Involvement in Synaptic Function and Neuronal 
Migration
Atsuko Hiroi1, Tomoko Yamamoto1, Noriyuki Shibata1, Makiko Osawa2 and 
Makio Kobayashi1
1Department of Pathology, School of Medicine, Tokyo Women’s Medical University and 2Department of Pediatrics, School of 
Medicine, Tokyo Women’s Medical University, 8–1 Kawata-cho, Shinjuku-ku, Tokyo 162–8666, Japan
Correspondence to: Atsuko Hiroi, M.D., Department of Pathology,
Tokyo Women’s Medical University, 8–1 Kawata-cho, Shinjuku-ku,
Tokyo 162–8666, Japan. 
E-mail: dunziah@research.twmu.ac.jp
00 Received December 28, 2010; accepted March 15, 2011; published online April 21, 2011
© 2011 The Japan Society of Histochemistry and Cy- Fukutin is a gene responsible for Fukuyama-type congenital muscular dystrophy (FCMD),
accompanying ocular and brain malformations represented by cobblestone lissencephaly.
Fukutin is related to basement membrane formation via the glycosylation of α-dystoglycan
(α-DG), and astrocytes play a crucial role in the pathogenesis of the brain lesion. On the
other hand, its precise function in neurons is unknown. In this experiment, the roles of fukutin
in mature and immature neurons were examined using brains from control subjects and
FCMD patients and cultured neuronal cell lines. In quantitative PCR, the expression level of
fukutin looked different depending on the region of the brain examined. A similar tendency
in DG expression appears to indicate a relation between fukutin and α-DG in mature
neurons. An increase of DG mRNA and core α-DG in the FCMD cerebrum also supports
the relation. In immunohistochemistry, dot-like positive reactions for VIA4-1, one of the
antibodies detecting the glycosylated α-DG, in Purkinje cells suggest that fukutin is related
to at least a post-synaptic function via the glycosylation of α-DG. As for immature neurons,
VIA4-1 was predominantly positive in cells before and during migration with expression of
fukutin, which suggest a participation of fukutin in neuronal migration via the glycosylation
of α-DG. Moreover, fukutin may prevent neuronal differentiation, because its expression was
significantly lower in the adult cerebrum and in differentiated cultured cells. A knockdown
of fukutin was considered to induce differentiation in cultured cells. Fukutin seems to be
necessary to keep migrating neurons immature during migration, and also to support migra-
tion via α-DG.
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I. Introduction
Fukuyama-type congenital muscular dystrophy (FCMD)
is an autosomal recessive disease, which manifests as
muscular dystrophy with central nervous system (CNS) and
ocular malformations [2, 20]. The most common CNS lesion
is cobblestone lissencephaly of the cerebrum and cerebel-
lum. A gene responsible for FCMD is fukutin [9]. Fukutin is
related to the glycosylation of α-dystroglycan (DG), which
is involved in basement membrane formation. A product
from single DG mRNA is cleaved into α-DG and β-DG [13,
16]. α-DG is a heavily glycosylated extracellular protein
and one of the components of the dystrophin-glycoprotein
complex (DGC). The sugar chains of α-DG are receptors for
extracellular matrix proteins such as laminin, and glyco-
sylated α-DG is observed in the sarcolemma of the skeletal
muscle [13, 16]. Reduced glycosylation of α-DG causesHiroi et al. 92
muscular dystrophy [5].
The basement membrane covers the glia limitans, a
structure observed in the CNS surface, where the glyco-
sylated α-DG is observed [34]. In CNS lesions of FCMD
fetuses, glioneuronal tissues protrude into the leptomeninges
through disruptions of the glia limitans [18, 32, 34], in
which the glycosylation of α-DG is reduced [34]. Therefore,
hypoglycosylation of α-DG is considered to be a main cause
of the disruption of the glia limitans, resulting in the cobble-
stone lissencephaly. The glia limitans is formed by astro-
cytic endfeet, and in FCMD patients, the basement mem-
brane and cell membrane of astrocytes is abnormal, electron
microscopically [7, 31]. Astrocytes appear to be greatly in-
volved in the pathogenesis of the CNS lesion [34, 37]. On
the other hand, its function in neurons is unknown. Although
neurons do not form the basement membrane, both fukutin
and α-DG are expressed in mature and immature neurons
[24–26, 33, 37]. It has been supposed that fukutin partici-
pates in neuronal migration and synaptic function through
the glycosylation of α-DG by immunohistochemical studies.
However, quantitative analysis has yet to be done, and to the
best of our knowledge there are no biochemical analyses
that directly prove the relationship between fukutin and the
glycosylation of α-DG in neurons. Neurons are the leading
component in the CNS. To clarify the roles of fukutin in
neurons is indispensable for understanding the whole patho-
mechanism of CNS lesions of FCMD and for supporting a
future gene therapy.
In this study, we investigated whether expressions of
fukutin and α-DG differ in different regions of the brain,
whether fukutin works via α-DG in neurons, and whether
these expressions show developmental changes in neurons,
using brain tissues from neurologically normal control
subjects and FCMD individuals, as well as neuron cell
lines. Quantitative PCR analysis (qPCR) and immunohisto-
chemistry were performed. Moreover, RNA interference
(RNAi) was performed in a human neuroblastoma cell line
to evaluate influence on cellular differentiation of fukutin.
II. Materials and Methods
Brain tissues
For qPCR, brain tissues from a FCMD patient (aged
27 years) and 8 neurologically normal control subjects (5
fetuses aged 22 to 39 weeks of gestation [gw] and 3 adults
aged 56 to 77 years) were obtained at autopsy within 16 hr
after death. Tissue samples were immediately frozen and
stored at −80°C. Immunohistochemistry was performed on
brain tissues from 6 postnatal FCMD patients (aged 6 to 27
years) and 7 control subjects (aged 23 gw to 31 years) within
37 hr after death.
Each autopsy was performed after family members
granted informed consent in accordance with the Ethical
Guidelines of Tokyo Women’s Medical University and the
Helsinki Declaration.
Cell lines
Hybrid cell line consisting of murine spinal motor
neuron and neuroblastoma (NSC34) was purchased from
CELLutions Biosystems Inc (Ontario, Canada). Cells were
grown in high-glucose Dulbecco’s MEM (Invitrogen,
Carlsbad, CA, USA), supplemented with 10% fetal bovine
serum (Thermo Fisher Scientific, Waltham, MA, USA), 1%
penicillin-streptomycin (Invitrogen) and 2 mM glutamine
(Invitrogen). Cells were differentiated by treatment with
1:1 DMEM and Ham’s F12 (Invitrogen), supplemented with
1% FBS, 1% penicillin-streptomycin, 1% glutamine and 1%
MEM and non-essential amino acids solution (Invitrogen)
for 48 hr.
Human neuroblastoma cell line (IMR-32) was pur-
chased from Health Science Research Resources Bank
(Osaka, Japan). Cells were grown in MEM (Invitrogen),
supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin.
Cells were maintained at 37°C in a humidified incu-
bator with a 5% CO2 atmosphere.
RNA extraction and qPCR
On adult control subjects, tissue samples from the gray
matter of the frontal lobe, putamen, thalamus, hippocampal
head, parahippocampal gyrus, substantia nigra, red nucleus,
and inferior olivary nucleus were used. The inferior olivary
nucleus was obtained only from one case. On fetal control
subjects, tissue samples from the cerebrum and cerebellum
were used. On the FCMD patient, a tissue sample from the
cerebrum was used. RNA was extracted from brain tissues
with RNeasy Lipid Tissue Mini kit (Qiagen, Valencia, CA,
USA). Reverse-transcription was performed using Prime
Script RT-PCR kit (Takara, Tokyo, Japan).
qPCR was performed using the SYBR green method
on a Thermal Cycler Dice TP800 real time system (Takara)
according to the manufacturer’s instruction. Reactions were
set up with cDNA corresponding to 50 ng total RNA, prim-
ers (50 pM final concentration), and SYBR Premix ExTaq II
(Takara). The sequences of gene specific primers used were
as follows: fukutin forward 5'-CAT TCT GGC TGA GCA
GTG GAA C-3' /reverse 5'-GAA GTC CTG CAT CCT
GAA ATG CTA A-3', DG forward 5'-GCG CTC ATT TCG
AGT GAC CA-3' /reverse 5'-TGA GTC CCA GTG CAG
CCA AG-3'. The amplification profiles consisted of 95°C
for 10 sec, followed by 40 cycles at 95°C for 5 sec and 60°C
for 30 sec. At the end of each run, a melting point analysis
was performed to validate the specificity of the PCR prod-
ucts. The quality of the PCR products was also confirmed
by agarose-gel electrophoresis. All samples were analyzed
in triplicate. Four different housekeeping genes, β-actin,
GAPDH, HPRT1, and β2-microglobulin, were used to qual-
ify the expression levels of fukutin and DG mRNA. Since all
the housekeeping genes showed a similar result, β-actin
was used for the experiment of brain tissues. Primers of
housekeeping genes were purchased from Takara. Relative
quantification was performed using the ΔΔ Ct method.
For comparison of data between fetuses and adults, tissueRole of Fukutin in Neurons 93
sample from white matter of the neurologically normal adult
brain was used for standardization.
Antibodies
Primary antibodies used were anti-fukutin antibody
(rabbit, polyclonal [33]), anti-α-DG antibody against the
laminin binding site of glycosylated epitope of α-DG
(IIH6C4, mouse, monoclonal, Upstate Biotechnology, Lake
Placid, NY, USA), anti-α-DG antibody against glycosylated
epitope of α-DG (VIA4-1, mouse, monoclonal, Upstate
Biotechnology), and anti-α-DG antibody against core pep-
tide of α-DG (α-DG-p, sheep, polyclonal, generously pro-
vided by Dr. S. Kröger [6]).
Immunohistochemistry
All brain tissues were fixed in 10% formalin, em-
bedded in paraffin, and cut into 4-μm-thick sections. The
frontal or parietal lobe, thalamus, medulla oblongata, and
cerebellum were examined. Details of antibody dilution,
antigen retrieval, and detection methods are shown in
Table 1. Briefly, after deparaffinization, antigen retrieval
was performed. Sections were immersed in 0.3% hydrogen
peroxide for 10 min to quench endogenous peroxidase
activity. Nonspecific binding was blocked with 5% skim
milk for 10 min. The sections were then incubated overnight
at 4°C with primary antibody. The immunoproducts were
visualized with Liquid DAB+Substrate Chromogen System
(DAKO, Glostrup, Denmark). The specimens were counter-
stained with hematoxylin.
RNAi
RNAi was performed as described previously [36].
Stealth siRNA duplex for fukutin mRNA was designed
and synthesized by Invitrogen. The target sense for fukutin
was  5'-UUUGGAAGGGAACAAAUUUCCUGUC-3' (F697).
Scrambled negative control StealthTM RNA (SNC, Invitro-
gen) was used for negative control. Omission of siRNA was
always performed as a negative control in each experiment.
Neuroblastoma cells were plated one day before transfection
at a density of about 200,000 cells in each 35-mm dish.
Antibiotics were omitted from the medium. Then siRNA
(40 nM final concentration) was transfected into the cells
using lipofectamine MAX (Invitrogen) and Opti-MEM
(Invitrogen) according to the manufacturer’s instructions.
The culture medium was changed to the standard formu-
lation one day after transfection. Four days after transfec-
tion, cells were harvested and suppression of each gene was
confirmed by RT-PCR and/or real time PCR. Moreover the
length of neuronal processes was measured and the mean
length was calculated (control: n=128 neuronal processes,
and fukutin-knockdown cells: n=183 neuronal processes).
The measurement was performed on neuronal processes
whose branching from the cell body was clearly determined,
and a length between the cell surface to the terminal of neu-
ronal process was measured.
Statistical analysis
The significance of differences between groups was
evaluated by unpaired t-test, Mann-Whitney test, and non-
repeated ANOVA. Values of p<0.05 were considered signif-
icant.
Table 1. Primary antibodies for immunohistochemistry
CSA: catalyzed signal amplification (CSA system, Dako).
polymer HRP: polymer horseradish peroxidase (EnVision, Dako).
ABC: avidin-biotin-peroxidase complex (Vectastatin ABC system,
Vector laboratories).
antigen dilution antigen retrieval detection
fukutin 1:50 0.1% trypsin, 
37°C 30 min.
CSA or polymer HRP
IIH6C4 1:1000 citrate pH 6.0, 
MW 20 min.
polymer HRP
VIA4-1 1:50 citrate pH 6.0, 
MW 20 min.
polymer HRP
α-DG-p 1:1000 EDTA pH 9.0, 
MW 40 min.
ABC
Fig. 1. Relative expression of fukutin (A) and DG mRNA (B) in
different regions of the adult control brain. A. The expression of
fukutin mRNA is significantly higher in the cerebellum compared
to that in the cerebrum. Its expressions in the other 6 portions are
relatively equivalent. B. The pattern of expression tends to be simi-
lar to that of fukutin, but the difference does not reach significance.
Whiskers indicate the standard deviation. FKTN, fukutin; DG,
dystroglycan; Cx, cerebral cortex; Cb, cerebellum; Th, thalamus;
Pu, putamen; Hh, hippocampal head; Ph, parahippocampal gyrus;
SN, substantia nigra; RN, red nucleus; IO, inferior olivary nucleus.Hiroi et al. 94
III. Results
Regional differences in fukutin and DG expressions in the 
adult control brain
On qPCR, the relative expression level of fukutin
mRNA was significantly higher in the cerebellum than in the
cerebral cortex. Its expression was relatively equivalent in
the cerebral cortex, thalamus, putamen, hippocampal head,
parahippocampal gyrus, substantia nigra, and red nucleus
(Fig. 1A). The expression level of DG mRNA tended to be
similar to that of fukutin mRNA (Fig. 1B). Its expression in
the cerebellum tended to be increased, but the difference was
not significant.
On immunohistochemistry of the adult brain, neurons
were basically positive for fukutin, VIA4-1, and α-DG-p.
The cytoplasm, nucleus, and neuropil were stained, but there
were some differences in expression levels. In contrast,
IIH6C4 was negative in neurons and neuropil in all regions
of the brain (Fig. 2A–P).
In the cerebral cortex (Fig. 2A–D), neurons were
focally positive for fukutin and positive for α-DG-p, while
VIA4-1 was weakly positive in the nuclei of neurons.
Fig. 2. Immunohistochemistry of fukutin and α-DG in the adult control brain. Fukutin, α-DG-p and VIA4-1 are basically positive in neurons
and neuropil, while IIH6C4 is negative in neurons and neuropil. A–D. Cerebral cortex. Pyramidal cells are focally positive for fukutin, weakly
positive in the nucleus for VIA4-1, and positive for α-DG-p. E–H. Cerebellum. Many cells in granular layer and small cells in the deep molec-
ular layer (arrows) are positive and Purkinje cells are weakly positive for fukutin and α-DG-p. VIA4-1-positive dots fringed the cell soma and
proximal dendrite of Purkinje cells (arrowheads). I–L. Thalamus. Thalamic neurons are positive for fukutin, VIA4-1 and α-DG-p. M–P. Infe-
rior olivary nucleus. Neurons are positive for fukutin, weakly positive for VIA4-1, and strongly positive for α-DG-p. DG, dystroglycan; Cx,
cerebral cortex; Cb, cerebellum; Th, thalamus; IO, inferior olivary nucleus. Bar=50 μm.Role of Fukutin in Neurons 95
In the cerebellum (Fig. 2E–H), most of the cells in the
granular layer were positive for fukutin and α-DG-p and
weakly positive for VIA4-1. Purkinje cells were weakly
positive for fukutin, VIA4-1, and α-DG-p. Interestingly, cell
soma and proximal dendrite of Purkinje cells were fringed
by VIA4-1-positive dots. Small cells, suggestive of basket
cells, in the molecular layer were positive for fukutin and
α-DG-p.
Thalamic neurons were positive for fukutin, VIA4-1,
and α-DG-p (Fig. 2I–L). Neurons of the medulla oblongata
were generally positive for fukutin, VIA4-1, and α-DG-p
(Fig. 2M–P). Especially, neurons of the inferior olive were
strongly positive for α-DG-p.
Alteration of α-DG expression in the postnatal FCMD 
cerebrum
On qPCR, the relative expression level of DG mRNA
in the cerebral cortex of FCMD tended to be increased
compared to that in controls (Fig. 3).
On immunohistochemistry of the FCMD cerebral cor-
tex (Fig. 4A–C), IIH6C4 was negative, VIA4-1 was mostly
negative except nucleus and α-DG-p was strongly positive
in neurons and neuropil. Compared to that in age-matched
controls (Fig. 4D–F), immunoreactivity to α-DG-p showed
a clear difference, being stronger in the neuronal cytoplasm
of FCMD patients than in that of adult control subjects
(Fig. 4C, F).
Developmental changes in fukutin and α-DG in the control 
cerebrum and cerebellum
On qPCR, the relative expression of fukutin mRNA
was significantly higher in the fetal cerebral cortex than
in the adult cerebral cortex (Fig. 5A). In contrast, the adult
cerebellar cortex tended to show greater fukutin expression
than the fetal cerebellar cortex (Fig. 5B). The expression
of DG mRNA tended to be similar to that of fukutin
(Fig. 5A, B).
On immunohistochemistry of the fetal cerebrum
(Fig. 6A–D), fukutin and α-DG-p were positive in the
cytoplasm and nucleus of many cortical neurons, cells in
the white matter, probably migrating neurons, and peri-
ventricular cells including cells in the ventricular and
periventricular zone. IIH6C4 was negative, but VIA4-1
was positive in some cortical neurons and the majority of
cells in the white matter and periventricular cells, and the
Fig. 3. Relative expression of DG
mRNA in the cerebrum of postnatal
FCMD and adult controls. DG
mRNA expression level in FCMD
tends to be higher than that in the
control. Whisker indicates the stand-
ard deviation. FCMD, Fukuyama-type
congenital muscular dystrophy; DG,
dystroglycan; Cont, control.
Fig. 4. Immunohistochemistry of α-DG in postnatal FCMD patients (A–C) and age-matched controls (D–F). In FCMD, pyramidal neurons are
negative for IIH6C4 and positive reaction for VIA4-1 appears to be reduced. Immunoreaction for α-DG-p in neurons and neuropil is stronger in
FCMD than in the control (C, F). FCMD, Fukuyama-type congenital muscular dystrophy; DG, dystroglycan. Bar=50 μm.Hiroi et al. 96
positive reactions of later two areas were at a similar level.
Compared to those in the adult cerebrum (Fig. 6E–H),
fukutin and α-DG-p expressions were stronger in the fetal
cerebrum. In the fetal cerebellar cortex (Fig. 6I–L), fukutin
was positive in the external granular and Purkinje cell
layers and weakly positive in some neurons of the internal
granular layer. IIH6C4 was negative. VIA4-1 was positive
in the external and internal granular layers and in some neu-
rons of the Purkinje cell layer, while α-DG-p was positive
in all layers. Periventricular cells and cells in the white
matter were positive for fukutin, VIA4-1 and α-DG-p. Com-
pared to those in the adult cerebellum (Fig. 6M–P), positive
reactions for fukutin and α-DG-p were stronger in Purkinje
cells. Cells in the internal granular layer appeared to main-
tain their expression after maturation.
Differentiation-related alteration in the murine neuronal cell 
line, NSC34
NSC34 contains two populations of cells: small cells
derived from murine spinal motor neurons, and larger
multinucleated cells derived from murine neuroblastoma
cells (Fig. 7A). After differentiation (d-NSC34), small cells
extended neuronal processes prominently (Fig. 7B). The
expression of fukutin mRNA was significantly lower in
d-NSC34 than in NSC34 (Fig. 7C). The expression of DG
mRNA was apparently decreased in d-NSC34, but the
difference did not reach significance (Fig. 7D).
RNAi in human neuroblastoma cells, IMR-32
After knockdown of fukutin, cells showed marked
outgrowth of neuronal processes compared to control cells
(Fig. 8A, B). The length of neuronal processes of fukutin-
knockdown cells (44.2±30.3 μm) was significantly longer
than that of control cells (16.4±9.6  μm) (Fig. 8C). The
expression of fukutin mRNA was significantly decreased in
fukutin-knockdown cells compared to that of control cells
(Fig. 8D). There was no decrease of fukutin mRNA in cells
treated with SNC. There was no significant difference in DG
mRNA expression between fukutin-knockdown cells and
control cells (Fig. 8D).
IV. Discussion
Fukutin is known to be expressed in neurons, but it
remains to be clarified whether the expression and function
of fukutin in each kind of neuron are the same or not.
The present qPCR study demonstrated that fukutin was
expressed in 9 different regions of the neurologically normal
adult brain. Moreover, the amounts of fukutin mRNA
differed somewhat from region to region. On immuno-
histochemistry of adult control brains, the cytoplasm and
nucleus of most of the neurons was basically positive for
fukutin, indicating that both excitatory and inhibitory
neurons express fukutin. Some variations in positive reac-
tions support the result of qPCR: the expression of fukutin
may be somewhat different depending on the kind of neuron
involved.
The relative expression of fukutin mRNA was sig-
nificantly higher in the cerebellum compared to that in
other regions of the brain. This difference may be derived
from differences in synapse numbers and the presence of
cerebellum-specific cells such as Purkinje cells and gran-
ule cells. Actually, the positive reaction in the internal
granular layer remains after development [24, 33], as seen
in this study.
On immunohistochemistry, the co-expression of fuku-
tin and α-DG has been reported in various neurons in mice
[19]. In the human brain, the relation between fukutin and
Fig. 5. Relative expression of fukutin and DG mRNA in control
fetuses and adults. A. Cerebral cortex. The expression of fukutin
mRNA is significantly higher in the fetal cerebrum than in the adult
cerebrum. The expression of DG mRNA tends to be similar to that
of fukutin. B. Cerebellum. In contrast to the cerebrum, the adult
cerebellum tends to show higher expressions of fukutin and DG
mRNA than the fetal cerebellum. Whiskers indicate the standard
deviation. FKTN, fukutin; DG, dystroglycan.Role of Fukutin in Neurons 97
the glycosylation of α-DG has been suggested only in
hippocampal neurons [25]. In this study, the expression of
fukutin and glycosylated α-DG was observed in the neurons
of other regions, immunohistochemically. Moreover, on
qPCR, the variations in the expression levels were similar
between fukutin and DG. Although tissue samples for qPCR
contained neurons and other components of the CNS, this
finding supports the view that fukutin and α-DG are closely
related in neurons as well, and that their expression showed
regional differences.
In the cerebral cortex of FCMD patient, qPCR showed
that the expression of DG mRNA tended to be increased
Fig. 6. Immunohistochemistry of fukutin and α-DG in control fetuses and adults. Neurons are negative for IIH6C4 in both fetuses and adults. A–
D. Fetal cerebral cortex. Many cortical neurons are positive for fukutin (A) and α-DG-p (D). Some cortical neurons and many periventricular
cells including cells in the ventricular and periventricular zone (inset) are positive for VIA4-1 (C). E–H. Adult cerebral cortex. Compared to
those in the fetal cortex, the expressions of fukutin and α-DG are apparently decreased. I–L. Fetal cerebellar cortex. Fukutin is positive in the
external granular and Purkinje cell layers and weakly positive in some neurons of the internal granular layer. VIA4-1 is positive in the external
and internal granular layers and in some neurons of the Purkinje cell layer. α-DG-p is positive in all layers. M–P. Adult cerebellum. Compared
to the fetal cerebellum, the expressions of fukutin and α-DG are apparently decreased in Purkinje cells. Immunoreaction in the granular layer
appears to be preserved. DG, dystroglycan; Cx, cerebral cortex; Cb, cerebellum; Eg, external granular layer; Pc, Purkinje cell layer; Ig, Internal
granular layer. Bar=50 μm.Hiroi et al. 98
compared to that in the control, and that the immuno-
reactivity against α-DG-p was stronger in neurons of FCMD
patients than in those of control subjects. These findings
may reflect a negative feedback of DG production against
hypoglycosylation of α-DG, disrupted intracellular transport
of unglycosylated DG, and/or impaired DG-degradation.
Alteration of neuronal DG expression associated with ab-
normal fukutin reduction in FCMD patients also supports
a functional linkage between fukutin and α-DG in human
neurons. RNAi of IMR-32 could not reveal a significant
change in DG mRNA. This is probably because the experi-
mental period was short.
Interestingly, cell soma and proximal dendrite of
Purkinje cells were fringed by VIA4-1-positive dots. This
dot-like positivity of VIA4-1 could correspond to both
inhibitory and excitatory synapses, because similar dot-like
immunodeposits in neurons including Purkinje cells have
been reported on immunostaining of GABAA and glutamate
receptors in the brain and cultured cells of rodents [4, 8],
and inhibitory and excitatory synapses are distributed re-
spectively in cell soma and proximal dendrite of Purkinje
cells [21]. α-DG co-localizes with GABAA receptors and
post-synaptic densities of excitatory synapses in the mouse
brain [11, 38]. Brain-selective DG-knockout mice show
severely blunted hippocampal long-term potentiation [17].
Taken together, fukutin may be involved in at least post-
synaptic function of mature human neurons through the
glycosylation of α-DG. In this study, the dot-like positivity
of VIA4-1 was observed only in Purkinje cells. This reaction
may be unique to Purkinje cell, because Purkinje cell has
a higher molecular weight of α-DG than other kinds of
neurons in mice [27]. However, diffuse immunoreactions of
the cytoplasm might mask dot-like reactions in other
neurons, because of the differences of α-DG amount and/or
cell size.
Fig. 7. Differentiation-related alteration in murine neuronal cells,
NSC34.  A. NSC34. NSC34 contains small cells (arrowhead)
derived from murine spinal motor neurons, and larger multinucle-
ated  cells  derived  from  mouse  neuroblastoma  cells  (asterisk).
B. d-NSC34. Small cells extend neuronal processes (arrowhead).
Asterisk: neuroblastoma cells. Bar=50 μm. C. Relative expression
of fukutin and DG mRNA. The expression of fukutin mRNA is
significantly lower in d-NSC than in NSC34. The expression of
DG tends to be similar to that of fukutin. Whiskers indicate the
standard deviation. FKTN, fukutin; DG, dystroglycan.
Fig. 8. RNAi in neuroblastoma cells, IMR-32. Compared to the con-
trol (A), cells show marked outgrowth of neuronal processes after
knockdown of fukutin (B). Bar: 50=μm. C. Length of neuronal
processes. Length of neuronal processes is significantly longer in
fukutin-knockdown cells than in control cells. D. Relative expres-
sion of fukutin and DG mRNA. The expression of fukutin mRNA
is significantly decreased in fukutin-knockdown cells compared to
that in control cells. The expression of DG mRNA does not show a
significant difference. mRNA level of fukutin and DG normalized
by GAPDH tends to be similar to those normalized by β-actin.
Whiskers indicate the standard deviation. FKTN, fukutin; DG,
dystroglycan; Cont, control; KD, knockdown.Role of Fukutin in Neurons 99
In this study, we used three kinds of anti-α-DG anti-
bodies, recognizing the core peptide of α-DG (α-DG-p), the
glycosylated epitope of α-DG (VIA4-1), and the laminin
binding site (IIH6C4). α-DG-p and VIA4-1 were positive
in the cytoplasm and nucleus of neurons and neuropil.
In contrast, IIH6C4 was negative. The target molecule of
VIA4-1 is still unidentified [12], but VIA4-1 probably
recognizes glycosylated epitopes other than the laminin
binding site, because the molecule reacting with VIA4-1
does not bind to laminin [1, 15]. Although an amount of α-
DG detected by IIH6C4 might be very small in neurons, the
α-DG expressed in neurons might have its own glycosylated
epitopes.
The function of fukutin and α-DG in immature neurons
is unclear. However, in addition to the over-migration of
immature neurons due to abnormal glia limitans, migration
arrest is suggested from several neuropathological findings,
like heterotopic neurons of the white matter of the FCMD
brain [37]. This phenomenon may be derived from a
neuronal abnormality. In the human fetal cerebrum, VIA4-1
was positive in some cortical neurons and the majority of
migrating neurons and periventricular cells including cells
in the ventricular and subventricular zone, while fukutin and
α-DG-p were positive in all areas. Fukutin may be involved
in the neuronal migration, relating to the glycosylation of α-
DG. The histology of the cerebral cortex appeared normal in
NEX-Cre/DG-null mice showing neuron-specific deletion
of DG, and it was suggested that neuronal DG is not critical
for neuronal migration [27]. However, the defect of DG in
more primitive cells may induce abnormal neuronal migra-
tion [17, 27]. Immature neurons migrate along the so-called
radial glial processes [29], interacting with various extra-
cellular proteins including agrin [22, 23, 30]. Some of the
extracellular matrix proteins might react with a glycosy-
lated epitope of α-DG other than the laminin-binding site,
because the sugar chains of α-DG are the receptors of
several extracellular matrix proteins [13, 16, 23]. In the
cerebellum, immature cells in the lateral surface of the
fourth ventricle migrate in a tangential manner to form the
external granular layer, cells of which then migrate inward-
ly. Positive reaction of fukutin and VIA4-1 in external
granular layer cells that are in the way of migration, also
support the view that fukutin participates in cerebellar neu-
ronal migration via the glycosylation of α-DG.
The present study demonstrated that the expression of
fukutin mRNA was decreased with maturation in the human
cerebrum. DG mRNA showed a tendency similar to fukutin
mRNA. This is compatible with the findings of several
previous studies [24, 33]. In the murine cell line, NSC34,
the expression of fukutin mRNA was decreased with cell
differentiation. In the human neuroblastoma cell line, IMR-
32, showed a significant neuronal process-outgrowth by
knockdown of fukutin. Because fukutin appears to prevent
cellular differentiation in astrocytoma cell line (data not
shown), a similar role could be considered in IMR-32. Func-
tional analyses were not performed in this experiment, but
the elongation of neuronal processes seems to indicate
cellular differentiation. DG-knockout chick embryos show
an increase in the thickness of the neuroepithelial cell layer
and loss of their radial morphology [28]. Fukutin might
be involved in cellular differentiation via glycosylation of
α-DG. Immature neurons are in an immature state during
migration, and begin to develop to a mature form once they
reach the proper position after migration. Fukutin appears
to be important not only simply for migration, but also
for preventing differentiation during migration. However,
further investigation is needed to clarify this point.
In contrast to those in the cerebrum, the expressions of
fukutin and DG mRNA were increased with maturation in
the cerebellum. The reason for this contradictory finding is
obscure. There is a possibility of sampling error because the
fetal cerebellum is very small and fragile, or a difference in
components comprising the cerebellum.
Taken together, fukutin and α-DG are closely related
in mature and immature human neurons in vivo, such as
skeletal muscles and astrocytes. Fukutin may participate not
only in basement membrane formation but in synaptic
function and neuronal migration via the glycosylation of
α-DG. Moreover, it may have other functions presumably
relating to cellular differentiation.
In fukutin-transfected cultured cells, the transgene
products are restricted to the Golgi apparatus which is the
site of α-DG glycosylation [9, 14]. If the function of fukutin
is only related to the glycosylation of α-DG, fukutin expres-
sion should be restricted to the Golgi apparatus, but our
immunohistochemistry showed positive reactions of fukutin
in the entire neuronal cytoplasm, nucleus, and neuropil.
Possible nuclear and cytoplasmic localizations besides the
Golgi apparatus have been observed in carcinoma [36] and
astrocytoma cell lines (data not shown). Furthermore, β-DG
localizes at the nucleus and cytoplasm besides the Golgi
apparatus in cultured cells [3]. Because α- and β-DG gener-
ally co-localize, α-DG could also localize in the nucleus and
cytoplasm of neurons. Because a binding of fukutin and α-
DG is suggested [35], it is likely that fukutin has as of yet
unknown distinctive functions that co-operate with α-DG.
Since there is an alternative splicing in fukutin [10], nuclear
and cytoplasmic staining might be derived from isoforms.
However, these isoforms are originated from a single mRNA
and our present results seems to elucidate at least a part of
the characteristics and functions of fukutin.
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